Published February 1, 2012 - More info
Wounds that fail to heal in a timely manner, for example, diabetic foot ulcers, pose a health, economic, and social problem worldwide. For decades, conventional wisdom has pointed to growth factors as the main driving force of wound healing; thus, growth factors have become the center of therapeutic developments. To date, becaplermin (recombinant human PDGF-BB) is the only US FDA-approved growth factor therapy, and it shows modest efficacy, is costly, and has the potential to cause cancer in patients. Other molecules that drive wound healing have therefore been sought. In this context, it has been noticed that wounds do not heal without the participation of secreted Hsp90α. Here, we report that a 115-aa fragment of secreted Hsp90α (F-5) acts as an unconventional wound healing agent in mice. Topical application of F-5 peptide promoted acute and diabetic wound closure in mice far more effectively than did PDGF-BB. The stronger effect of F-5 was due to 3 properties not held by conventional growth factors: its ability to recruit both epidermal and dermal cells; the fact that its ability to promote dermal cell migration was not inhibited by TGF-β; and its ability to override the inhibitory effects of hyperglycemia on cell migration in diabetes. The discovery of F-5 challenges the long-standing paradigm of wound healing factors and reveals a potentially more effective and safer agent for healing acute and diabetic wounds.
Chieh-Fang Cheng, Divya Sahu, Fred Tsen, Zhengwei Zhao, Jianhua Fan, Rosie Kim, Xinyi Wang, Kathryn O’Brien, Yong Li, Yuting Kuang, Mei Chen, David T. Woodley, Wei Li
Original citation: J. Clin. Invest. 2011;121(11):4348–4361. doi:10.1172/JCI46475.
Citation for this corrigendum: J. Clin. Invest. 2012;122(2):779. doi:10.1172/JCI62538.
In Figure 2, concentrations of the recombinant Hsp90α added to the real wounds in mice were inaccurate. The correct figure and legend appear below.
F-5 is superior to FDA-approved becaplermin/PDGF-BB in acute wound healing. Full-thickness skin wounds (1 cm × 1 cm) in athymic nude mice were treated (only once on day 0) with either 200 μl of 5% CMC gel (placebo) or the same volume of the gel containing an optimized concentration of a given peptide: (A) full-length, (B) F-2, (C) F-5, (D) F-6 (n = 3 mice per peptide, per experiment), or (E) becaplermin (20 μg of PDGF-BB or 8 μM). Plus signs indicate treated mice, and minus signs indicate placebo mice. The images of 1 representative experiment are shown.
The authors regret the error.